Announcements Trials
Browse Landscape

Phase

Phase NA 8Phase 2 5Phase 3 4Phase 1/2 2Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 78Cyclophosphamide 55Specimen Handling 53Carboplatin 49fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Gemcitabine 37Biopsy 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Cisplatin 24Pemetrexed 23Ipilimumab 22Capecitabine 21Temozolomide 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Fulvestrant 18Cetuximab 18Azacitidine 17Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Radiation Dose Hypofractionation × 90 days × Clear all
NCT04172532 2026-06-02

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
92 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡